TipRanks
Advertisement
Advertisement

DYN Stock Latest News

Dyne Therapeutics: Growing Clinical Evidence for z-basivarsen Supports Outperform/Buy Rating and Maintained $40 Price Target
RatingsDyne Therapeutics: Growing Clinical Evidence for z-basivarsen Supports Outperform/Buy Rating and Maintained $40 Price Target
18d ago
DYN
Dyne Therapeutics price target lowered to $32 from $50 at H.C. Wainwright
PremiumThe Fly
Dyne Therapeutics price target lowered to $32 from $50 at H.C. Wainwright
18d ago
DYN
Dyne Therapeutics Highlights New ACHIEVE DM1 Trial Data
PremiumCompany Announcements
Dyne Therapeutics Highlights New ACHIEVE DM1 Trial Data
19d ago
8K
DYN
Piper confident Dyne’s Zeleciment rostudirsen will win January FDA approval
PremiumThe Fly
Piper confident Dyne’s Zeleciment rostudirsen will win January FDA approval
19d ago
DYN
NVS
Dyne Therapeutics management to meet with Piper Sandler
PremiumThe Fly
Dyne Therapeutics management to meet with Piper Sandler
20d ago
DYN
Buy/Sell: Wall Street’s top 10 stock calls this week
PremiumThe FlyBuy/Sell: Wall Street’s top 10 stock calls this week
1M ago
DYN
NKE
Midday Fly By: Analog acquires Alif, Independence Realty merges with Centerspace
Premium
The Fly
Midday Fly By: Analog acquires Alif, Independence Realty merges with Centerspace
1M ago
BP
ADI
Uber initiated, Thermo Fisher upgraded: Wall Street’s top analyst calls
Premium
The Fly
Uber initiated, Thermo Fisher upgraded: Wall Street’s top analyst calls
1M ago
CI
DYN
Dyne Therapeutics price target lowered to $36 from $45 at Morgan Stanley
PremiumThe Fly
Dyne Therapeutics price target lowered to $36 from $45 at Morgan Stanley
1M ago
DYN
NVS
Dyne Therapeutics price target lowered to $30 from $35 at RBC Capital
PremiumThe Fly
Dyne Therapeutics price target lowered to $30 from $35 at RBC Capital
1M ago
DYN
Dyne Therapeutics price target lowered to $26 from $30 at Baird
PremiumThe Fly
Dyne Therapeutics price target lowered to $26 from $30 at Baird
1M ago
DYN
Dyne Therapeutics downgraded to Underweight from Neutral at JPMorgan
PremiumThe Fly
Dyne Therapeutics downgraded to Underweight from Neutral at JPMorgan
1M ago
DYN
NVS
Dyne Therapeutics falls -15.4%
PremiumThe FlyDyne Therapeutics falls -15.4%
1M ago
DYN
Dyne Therapeutics falls -22.3%
Premium
The Fly
Dyne Therapeutics falls -22.3%
1M ago
DYN
Video: Novartis slides after second recent drug development setback
Premium
The Fly
Video: Novartis slides after second recent drug development setback
1M ago
P
BE
Dyne Therapeutics: Buy Rating Backed by Late-Stage Muscle Disease Platform, Multibillion-Dollar Opportunities, and Dual-Path Approval Strategy
PremiumRatings
Dyne Therapeutics: Buy Rating Backed by Late-Stage Muscle Disease Platform, Multibillion-Dollar Opportunities, and Dual-Path Approval Strategy
1M ago
DYN
Dyne Therapeutics should be bought on weakness, says Stifel
PremiumThe Fly
Dyne Therapeutics should be bought on weakness, says Stifel
1M ago
DYN
NVS
Dyne ‘claims frontrunner status in DM1’ after Novartis failure, says Jefferies
PremiumThe Fly
Dyne ‘claims frontrunner status in DM1’ after Novartis failure, says Jefferies
1M ago
DYN
NVS
Dyne Therapeutics sinks after Novartis myotonic dystrophy miss
PremiumThe Fly
Dyne Therapeutics sinks after Novartis myotonic dystrophy miss
1M ago
DYN
NVS
Dyne Maintained at Buy as Analyst Reaffirms $50 Price Target on Favorable DM1 Risk‑Reward Outlook
PremiumRatingsDyne Maintained at Buy as Analyst Reaffirms $50 Price Target on Favorable DM1 Risk‑Reward Outlook
2M ago
DYN
Dyne Therapeutics price target lowered to $45 from $47 at Morgan Stanley
Premium
The Fly
Dyne Therapeutics price target lowered to $45 from $47 at Morgan Stanley
3M ago
DYN
Dyne Therapeutics reports Q2 EPS ($1.08), consensus (75c)
Premium
The Fly
Dyne Therapeutics reports Q2 EPS ($1.08), consensus (75c)
3M ago
DYN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >